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Abstract
There have been renewed interests in natural products as drug discovery sources. In particular, natural product
combinations have been extensively studied, clinically tested, and widely used in traditional, folk and alternative medicines.
But opinions about their therapeutic efficacies vary from placebo to synergistic effects. The important questions are
whether synergistic effects can sufficiently elevate therapeutic potencies to drug levels, and by what mechanisms and at
what odds such combinations can be assembled. We studied these questions by analyzing literature-reported cell-based
potencies of 190 approved anticancer and antimicrobial drugs, 1378 anticancer and antimicrobial natural products, 99
natural product extracts, 124 synergistic natural product combinations, and 122 molecular interaction profiles of the 19
natural product combinations with collective potency enhanced to drug level or by .10-fold. Most of the evaluated natural
products and combinations are sub-potent to drugs. Sub-potent natural products can be assembled into combinations of
drug level potency at low probabilities by distinguished multi-target modes modulating primary targets, their regulators
and effectors, and intracellular bioavailability of the active natural products.
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Introduction
Natural products (NP) have been traditional sources of drug
discovery and there are renewed interests in them for new drug
discovery [1], [2], [3], [4]. In particular, NP combinations have
been extensively studied [5], [6], tested in clinical trials [7], [8],
[9], and widely used in traditional, folk and alternative medicines
[10], [11]. Their novel multi-targeted mechanisms [8], [12], [13]
or molecular scaffolds [14] may be valuable sources for developing
multi-targeted therapeutics [15]. Opinions vary regarding to the
therapeutic efficacies of NP combinations. One attributes the
efficacies of NP combinations to placebo effects [16], [17], [18]
based on indications from clinical trials [17], [18] and the findings
that bioactive NPs are typically sub-potent to drugs [19], [20].
Another credits the efficacies of NP combinations to synergistic
effects [6], [8], [19], [21], [22] based on the findings that some NP
combinations produce significantly better effects than equivalent
doses of their components [19], [22] and clinical outcomes are not
necessarily influenced by positive beliefs [16].
The contribution of synergistic effects to therapeutic efficacies
has been extensively studied [6], [8], [22]. While many studies
have consistently suggested that therapeutic potency can be
enhanced by synergistic effects, the levels of potency enhancement,
particularly with respect to those of drugs, have not been
sufficiently studied to quantitatively assess the contribution of
synergism to the therapeutic efficacies of NP combinations. In
particular, four important questions need to be answered: what are
the gaps between the potencies of the typically studied bioactive
NPs and those of drugs, whether synergistic combination of sub-
potent NPs can sufficiently enhance their collective potencies to
reach drug potency level, and at what odds and by what molecular
modes such NP combinations can be assembled.
The first question was studied by analyzing the literature-
reported cell-based potencies of 190 approved drugs and 1378 NPs
of anticancer and antimicrobial classes. Potencies derived from
cell-based assays were used instead of target-based and in-vivo
assays for several reasons. To a certain extent, cell-based assays
can predict in-vivo activities [23], [24] and these assays have been
successfully used for discovering therapeutic agents that have
entered advanced development stages [25]. Within the same
disease classes, cell-based assays are more mutually comparable
and better reflecting overall effects than target-based assays. The
number of NPs with cell-based potency data is significantly higher
than those with in-vivo data. The anticancer and antimicrobial
classes were particularly focused because of the availability of
statistically significant number of cell-based activity data, the
relatively comparable bioassays than some other therapeutic
classes, and the relevance to our NP combination studies (67%
of our studied synergistic NP combinations are from these two
classes).
The second question was addressed by evaluating 124
literature-reported synergistic combinations of 158 NPs with cell-
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based activity data available for all of the constituents both in
individual and in the respective combination. These data are
necessary for deriving combination index (CI) and dose reduction
index (DRI) for rigorous evaluation of synergistic effects [26]. The
third question was probed by analyzing 122 molecular interaction
profiles (MIPs) in 19 NP combinations with potencies enhanced to
drug level or by over 10-fold. These MIPs are linked to the
potency-enhancing synergistic molecular modes involving collec-
tive modulation of the primary targets, their regulators and
effectors, and the pharmacokinetics of the active NP ingredients
[8], [12].
While these 122 MIPs have been individually reported in the
literatures, few of them have been collectively analyzed for probing
potency enhancing molecular modes in NP combinations. It is
cautioned that, although connections can be made between these
MIPs and the synergistic potency-enhancing modes, many of these
interconnections are much more complicated than those analyzed
here. Their activities are highly dynamic [27], [28], [29]
influenced by genetic variations [30], environmental factors [31],
host’s behavior [32], and therapeutic scheduling [33]. Their use
should be more appropriately viewed as a start to a more
comprehensive analysis of the potency-enhancing modes in NP
combinations.
Materials and Methods
Experimentally determined cell-based inhibitory activities of
anticancer and antibacterial drugs and NPs were searched from
the Pubmed database [34] by using keyword ‘drug’, ‘natural
product’, ‘herb’, ‘medicinal plant’, ‘extract’, ‘ingredient’, ‘GI50’,
‘IC50’, ‘MIC’, ‘‘activity’’, ‘cell-line’, and ‘in vitro’. Cell-based
inhibitory activities of 88 anticancer and 102 antimicrobial drugs
were obtained from the literatures and the NCI standard agent
database (Table S1 and S2). Their approval status was further
checked against the drug data in the Therapeutic target database
[35]. Cell-based inhibitory activities of 1378 anticancer and
antimicrobial NPs (Table S3 and S4) and 99 antimicrobial NP
extracts (Table S5) were obtained from the literatures. These
activities are typically given as GI50 or IC50 values against cancer
cell-lines or MIC values against microbial cells. For drugs and NPs
with multiple potency data, the best potency was selected.
Literature-reported synergistic NP combinations were searched
from the Pubmed database [34] by keywords ‘natural product’,
‘herb’, ‘medicinal plant’, ‘extract’, ‘ingredient’, ‘synergistic’,
‘synergy’, ‘synergism’, ‘synergize’, and ‘potentiate’. Although
many NP combinations are synergistic [6], [8], [22], only 124
synergistic combinations of 158 NPs are with sufficient cell-based
data for computing CI and DRI values (Table S6). The cell-based
activities of the constituent NPs in some of these combinations are
given in terms of the percent inhibitory rates at particular
concentrations. Their CI and DRI values were computed by using
the median effect equation, the multiple drug effect equation, and
the combination index theorem [26].
Results and Discussion
Comparison of the Potencies of Natural Products and
Drugs in Cell-based Assays
Drug potency is context dependent, varying with assay, target
and technology. Previous analysis has suggested that drugs in cell-
based assays typically exhibit potencies of #1 mM [36]. Hence, we
tentatively define drug potency level for anticancer and antimi-
crobial classes as GI50/IC50#1 mM and MIC#1 mg/mL re-
spectively, which are satisfied by 76% anticancer and 86%
antimicrobial drugs. In some cases, drug efficacy is not only
determined by cell-based activities. A minority of drugs sub-potent
in cell-based assays are nonetheless clinically efficacious by such
additional mechanisms as immuo- and hormone modulations [37],
[38]. While drug potency level can be more rigorously defined by
considering these mechanisms, few drugs and NPs have been
sufficiently studied for enabling such a consideration. It is more
practically feasible to tentatively focus on cell-based activities that
nonetheless reflect the potencies of most drugs and NPs.
Figure 1 and 2 show the potency distribution profiles of 88 and
650 anticancer drugs and NPs, and those of 102, 609 and 99
antimicrobial drugs, NPs and NP extracts respectively. The
median potencies of anticancer (GI50/IC50= 28 nM) and anti-
microbial (MIC=0.12 mg/mL) drugs are 214-fold and 104-fold
higher than those of anticancer (GI50/IC50=6 mM) and antimi-
crobial (MIC=12.5 mg/mL) NPs. Overall, 25% of the anticancer
and 10% of the antimicrobial NPs reach drug potency level, and
additional 33% of the anticancer and 37% of the antibacterial NPs
are within 10-fold range of drug potency level (1 mM,GI50/
IC50#10 mM, 1 mg/mL,MIC#10 mg/mL). The pool of potent
NPs is relatively small (10–25%). A significantly expanded pool of
active NPs (47–58%) may be explored if NP combinations of.10-
fold potency enhancement can be assembled at reasonable
probabilities. The potencies of the NP extracts are mostly 100–
1,000 folds lower than those of individual NPs, as the active
constituents only constitute a small portion of their contents [39].
Partly because of this gap, NP extracts have been typically
prescribed in g/kg [40], [41] in contrast to the mg/kg ranges for
drugs and NPs.
Synergistic Natural Product Combinations
Based on Chou’s method [26], the levels of synergism in the NP
combinations (Figure 3) were categorized into the levels of very
strong synergism (CI,0.1), strong synergism (CI= 0.1–0.3),
synergism (CI= 0.3–0.7), moderate synergism (CI= 0.7–0.85),
slight synergism (CI= 0.85–0.90), nearly additive (CI = 0.90–
1.10), slight antagonism (CI= 1.10–1.20), and moderate antago-
nism (CI= 1.20–1.45) respectively. Overall, 24% and 34% of the
combinations are at the strong/very strong synergism and
synergism levels, indicating that highly synergistic combinations
can be formed at fair probabilities. Figure 4 shows the potency
improvement profile of the NPs in these combinations, in which
4% and 19% of the NPs exhibit .100-fold and 10–100 fold
potency improvement respectively. This suggests that .10-fold
potency improvement is achievable at moderate probabilities.
These combinations are mostly composed of sub-potent NPs.
There are only 6 potent NPs, and 1 and 3 combinations fully and
partially composed of potent NPs. Synergism elevates the
collective potencies of 5 fully sub-potent and 2 partially sub-
potent combinations to drug level, and lifts the potency of 4 NPs in
another 3 sub-potent combinations to drug level. Overall, the
potencies of 22 (14.4%) sub-potent NPs and collective potencies of
7 (5.6%) sub-potent combinations are enhanced to drug level,
suggesting that the individual and collective potencies of sub-
potent NPs can be raised to drug level at moderate and low
probabilities respectively.
Potency Enhancing Molecular Modes of Natural Product
Combinations
The molecular mechanisms of synergism of drug combina-
tions [12] and NP combinations [8] can be studied from their
MIPs. We conducted comprehensive literature search for
identifying the targets and synergism-related MIPs of three
NP combinations with collective potencies improved to drug
Sub-Potent Natural Products as Potent Combinations
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levels, which identified 11 targets related to the reported
therapeutic effects of these combinations and 72 MIPs likely
contributing to the potency-enhancing modes (Table S7). The
targets and potency-enhancing MIPs of two of the NP
combinations are also summarized in Table 1 and 2. Specific
potency-enhancing molecular modes were identified. The
potencies of the principal NP in these combinations are at or
near drug potency level (IC50=0.8–1.1 mM, 0.94 mg/mL)
probably due in part to the multi-target activities of each
principal NPs (2, 4, 5 targets respectively). Network and activity
analysis have shown that weak inhibition of multiple targets in
related pathways may be more efficient than strong inhibition
against a single target [42], [43]. The potencies of the
companion NPs are substantially weaker (IC50=1.7–656 mM,
5.07–251 mg/mL). The potencies of all NPs in these combina-
tions are significantly enhanced (mostly by .10-fold) by multi-
target actions in modulating multiple regulators, partners and
effectors of the primary targets of the active NPs (complemen-
Figure 1. Potency distribution profiles of 88 and 650 anticancer drugs and natural products.
doi:10.1371/journal.pone.0049969.g001
Figure 2. Potency distribution profiles of 102, 609 and 99 antimicrobial drugs, natural products (NPs) and NP extracts.
doi:10.1371/journal.pone.0049969.g002
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tary actions), elevating intra-cellular bioavailability of the active
NPs, and antagonizing the processes counteractive to the
therapeutic effects of the active NPs (anti-counteractive actions).
Regulation of multiple regulators of the primary targets of
principal NPs is important for elevating the collective potencies to
drug level. In two combinations, 6 and 13 regulators of the
primary targets of the principal NPs are modulated. In the third
combination, each constituent NP targets one or two of the four
redundant processes to collectively achieve therapeutic effects.
These multi-target potency-enhancing modes are consistent with
the reports that weak inhibition of multiple targets in related
pathways may be more efficient than strong inhibition of a single
target [42], [43]. In these combinations, complementary actions
are achieved by modulating the expression, upstream regulators,
crosstalk/redundant signaling, and substrates/effectors of the
targets of individual NPs. Intra-cellular bioavailability of NPs are
enhanced by inhibiting/downregulating efflux pumps and upre-
gulating/activating cell-entry transporters. Anti-counteractive ac-
tions involve regulation of the pathways activated by the NPs that
subsequently reduce the therapeutic effects of the NPs. Drug
Figure 3. Synergism level of 124 synergistic NP combinations. VSS, SS, S, MS, sS: very strong, strong, normal, moderate, slight synergism, NA:
nearly additive, SA, MA: slight, moderate antagonism.
doi:10.1371/journal.pone.0049969.g003
Figure 4. The potency improvement profile of the constituent NPs.
doi:10.1371/journal.pone.0049969.g004
Sub-Potent Natural Products as Potent Combinations
PLOS ONE | www.plosone.org 4 November 2012 | Volume 7 | Issue 11 | e49969
efficacies are reportedly reduced by network robustness [44],
redundancy [45], crosstalk [46], and compensatory and neutral-
izing actions [47]. Our revealed potency-enhancing molecular
modes provide useful clues for reducing these literature-reported
negative effects by multi-targeted strategies.
Additional potency-enhancing mechanisms were studied by
analyzing 8 and 26 MIPs in 2 and 9 combinations with the
potency of the principal NP enhanced by .100-fold and 10–100
fold, and 16 MIPs of 5 combinations with the potency of a non-
principal NP improved by .10-fold respectively (Table S8, S9,
10). The potency of individual NPs in 13 combinations is
Table 1. The targets and potency-enhancing synergistic molecular modes of the anticancer combination of Tetraarsenic






Target, Therapeutic Effect or
Response (reference in
Pubmed ID) Effect type
Potency-Enhancing Synergistic Modes
(reference in Pubmed ID) Type of Synergism
Tetraarsenic tetrasulfide
[Principal] (1.1 uM) {6.88}
Degraded PML-RAR to produce anticancer
effect (18344322)
Growth inhibition, Indirubin blocked RAR-STAT3 crosstalk
(14959844) by reducing JAK/STAT3 signaling
((21207415). Tanshinone IIA reduced RAR
(12069693) by hindering AR (22175694,
22281759, 21997969). These complement
tetraarsenic tetrasulfide’s action on RAR
Complementary action




Indirubin inhibited and reduced CDK2
(18344322) to complement tetraarsenic
tetrasulfide’s action on CDK2
Complementary action
Upregulated RING-type E3 ligase c-CBL and
degraded BCR-ABL (21118980)
Growth inhibition




Indirubin and Tanshinone IIA upregulated




RARa reduction downregulated P53 and




Tanshinone IIA activated p53 signaling









Tetraarsenic tetrasulfide reduced CDK2
(18344322) to complement indirubin’s
action on CDK2
Complementary action
Inhibited GSK3 to produce anticancer
effect (21697283)
Growth inhibition
blocked VEGFR2 signaling (21207415) to





Activated AhR (20951181) which activates
RARa (16480812) to promote cancer
Counteractive action Tetraarsenic tetrasulfide degraded PML-RAR




[Cooperative ] (.3 uM)
{.9.38}
Increased Bax/Bcl-2 ratio, caspase 3,
reduced Bcl-2, mitochondrial membrane
potential, MMPs, to promote apoptosis
(21472292, 22002472, 22126901)
Apoptosis





Upregulated pP38 to enhance apoptosis
(21165580)
Apoptosis
Reduced HER2, NF-kBp65, RARa activities




Reduced and antagonized AR and
induced apoptosis (22175694, 22281759,
21997969)
Growth inhibition
pP38 upregulation (21165580) activated




Tetraarsenic tetrasulfide degraded PML-RAR
(18344322) to alleviate this counteractive
action
Anti-counteractive action
Upregulated efflux transporters to




Indirubin inhibit certain efflux pumps




The detailed descriptions of the relevant molecular interaction profiles are in Table S7.
doi:10.1371/journal.pone.0049969.t001
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enhanced by a single mechanism: enhancement of the intra-
cellular bioavailability of an active NP, which is an extensively-
explored effective potency-enhancing strategy for those NPs with
hindered intra-cellular bioavailability. In addition to actions on
efflux and cell-entry transporters, intra-cellular bioavailability of
NPs can be enhanced by regulating their metabolism, disrupting
membrane structures, and the use of pro-drug NPs of better cell-
entry abilities, The potency of individual NPs in the remaining 3
combination is enhanced by complementary and anti-counterac-
tive modes similar to those of the three NP combinations with
potencies improved to drug levels.
Although the potencies of some of the individual NPs in these
combinations are significantly improved, none is elevated to drug
level possibly due to low potencies of their principal NPs (44.6–
800 mg/mL with one exception) and modulation of few regulators
of the primary targets of the principal NPs. The success rate of
assembling sub-potent NPs into drug-level potent combinations
may be significantly improved by careful selection of principal NPs
of sufficient potency (e.g. potency ,10 mM) and the use of
cooperative NPs that enhance the bioavailability and modulate the
regulators, partners and effectors of the targets of the principal
NPs.
Influence of Individual Genetic Variations
Combinations of sub-potent NPs heavily rely on their synergistic
actions for improved potencies, which typically involve collective
modulation of a certain set of the primary targets and the
corresponding secondary targets. Because of their heavy reliance
on the modulation of the specific sets of secondary targets for
achieving sufficiently improved potency, the level of potency
improvement of synergistic NP combinations is expected to be
sensitively influenced by the genetic variations that alter the
expression and activity level of this set of targets [30]. Table 3
shows the expression profiles of the primary targets and some of
the potency-enhancing secondary targets of the selected NP
combinations in specific patient groups. The primary targets are
expressed in 42%–95% the patients and the secondary targets are
expressed in 15%–100% of the patients in different patient groups.
Significantly lower percentages of patients in each patient group
are expected to have the right set of the targets co-expressed to
make them responsive to a particular sub-potent NP combination.
Multi-herb combinations have been frequently prescribed in
personalized manner [48], [49] possibly out of the need for
exploiting certain potency-enhancing modes active in specific
patients.
Concluding Remarks
Our analysis indicates the possibility of synergistically assem-
bling sub-potent NPs into drug-level potent combinations, which
can be achieved at low probabilities by the exploration of specific
potency-enhancing modes that combine multi-target actions of the
principal NPs of sufficient potency (typically within 10-fold range
of drug potency levels) against specific disease processes with the
enhancement of their bioavailability and/or the modulation of the
regulators, effectors and counteractive elements of their targets.
The low probabilities for assembling sub-potent NPs into drug-
level potent combinations may arise from the difficulties in finding
the right combination of NPs with sufficient potency and the
appropriate and complementary potency-enhancing MIPs. More-
over, synergistic actions typically involve interactions with multiple
sites, targets and pathways which are sensitively influenced by
genetic [50], environmental [13], behavioral [51], and scheduling
[52] profiles. NP combinations and related therapeutics may be
better designed, applied and studied in personalized and
environment-dependent manners [53], [54]. The efforts in the
exploration of NP combinations can be facilitated by expanded
knowledge in the activities of NPs [55], MIPs of NPs [8], disease
regulations, and potency-enhancing molecular modes that syner-
Table 2. The targets and potency-enhancing synergistic molecular modes of the anti-rotavirus combination of Theaflavin,
Theaflavin-3-monogallate, Theaflavin-39-monogallate, and Theaflavin-3,39 digallate (anti-rotavirus synergism reported).
Natural Product [Role in
Combination] (Individual
Potency) { Dose Reduction
Index}
Target, Therapeutic Effect or Response
(reference in Pubmed ID) Effect type
Potency-Enhancing Synergistic
Modes (reference in Pubmed ID) Type of Synergism
Theaflavin [Principal] (0.943 ug/
mL) {9.33}
Reduced JNK and P38 phosphorelation
(21184129, 22111069) to block JNK and
p38 mediated viral replication
Viral replication
inhibition
Other 3 components block the redundant
Cox2 and ERK viral replication pathways
to complement Theaflavin’s activity
Complementary action
Theaflavin-3-monogallate




downregulated Cox2 (11103814) to block




All 4 components collectively cover 4









downregulated Cox2 (11103814) to block
Cox2 mediated viral replication
and infection (15331705, 17555580),
Viral replication
inhibition
All 4 components collectively cover 4












Other 3 components block the redundant
JNK, P38 and Cox2 viral replication
pathways to complement Theaflavin-3,39
digallate’s activity
Complementary action
Blocked NFkB activation (16880762) to
hinder NFkB and AkT mediated viral
survival and growth (20392855)
Viral survival,
growth inhibition
The detailed descriptions of the relevant molecular interaction profiles are in Table S7.
doi:10.1371/journal.pone.0049969.t002
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gistically target key positive [56] and negative [57] regulatory
nodes of therapeutic efficacies, and collectively modulate anti-
targets and counter-targets [58], compensatory and neutralizing
actions [47], [59], and transporter and enzyme mediated
pharmacokinetic activities [60].
Supporting Information
Table S1 Cell-based inhibitory activity data of 88 anticancer
drugs.
(PDF)
Table S2 Cell-based microbial inhibitory activity data of 102
antimicrobial drugs.
(PDF)
Table S3 Cell-based inhibitory activity values of 650 anticancer
natural products.
(PDF)
Table S4 Cell-based microbial inhibitory activity values of 609
antimicrobial natural products.
(PDF)
Table S5 Cell-based microbial inhibitory activity values of 99
antimicrobial natural product extracts.
Table 3. Expression profiles of the primary targets and some of the potency-enhancing secondary targets of the selected natural
product combinations in specific patient groups.
Natural Product
Combination Target Type Target Target Expression Profile in Specific Patient Groups
Tetraarsenic tetrasulfide,
Indirubin, and Tanshinone IIA
Primary target of the principal
ingredient
PML-RAR Present in 95% of APL patients (12506013)
Secondary target for enhancing
the potency of the principal
ingredient






Primary target of the principal
ingredient
JNK Expressed in 100% of patients with chronic obstructive pulmonary disease
(20699612), pJNK expressed in 100% of multiple trauma patients (22677613)
P38 Expressed in 82% patients with sepsis-induced acute lung injury (17581740),
pP38 expressed in 38% of multiple trauma patients (22677613)
Secondary target involved in the
alternative signaling that
substitute the targeted pathway of
the principal ingredient
Cox2 Expressed in 100% of HBV (15218507) and 100% of HCV (17845691) patients,
elevated in 100% of patients with HCV-induced chronic liver disease (18092051)
ERK pERK expressed in 15% of colorectal carcinoma (17149612), 39% of
mucoepidermoid carcinomas (12937136), 70% of breast cancer (15928662), 79%




Primary target of the principal
ingredient
AR Expressed in 59% of prostate cancer (22500161), 56%–63% of breast cancer
(18946753, 22471922), 80% of benign urothelium (22221549), 50% of benign
stroma (22221549), 42%–71% of bladder cancer (22221549) patients
Secondary target for enhancing
the potency of the principal
ingredient
c-Src Expressed in 55% of metastatic breast cancer (22716210), 74% of bladder cancer
(22353809), 28% of hormone refractory prostate cancer patients (19447874)
FGF1R Expressed in 69%–74% of prostate cancer (17607666), 99%–100% of breast
cancer (9865904, 9756721) patients
topoisomerase
II
Highly expressed and amplified in 50% and 5%–7% of breast cancer (22240029,
22555090), 31% and 26% of advanced prostate cancer (17363613), 20% and
1.5% of bladder cancer (11304849, 14566826) patients
CK2 Expressed in the bone marrow of 28% of the patients with transitional cell
carcinoma (17977715)
EGFR Expressed in 41% of prostate cancer (22500161), 25% of breast cancer
(22562124), 33% of triple negative breast cancer (22481575), 66%–96% of
bladder cancer (16685269, 19171060) patients
HER2 Expressed in 1.5%–24% of prostate cancer (19207111, 22500161), 8%–31%
breast cancer (10550311, 11344480, 22562124), 62%–98% of bladder cancer
(15839918, 16685269) patients
NF-kB Expressed in 53% of prostate cancer (21156016), 79% of bladder urothelial
carcinoma (18188593), active NF-kB present in 4.4%–43% of breast cancer
(16740744) patients
AkT pAkT expressed in 45% prostate cancer (19389013) and 33% breast cancer
(16464571), highly expressed in 2.6%–14.3% of patients with urothelial
carcinoma of the urinary bladder (21707707)
P53 Expressed in 22%–28% breast cancer (11344480), Overexpressed in 36% of
bladder cancer (19171060) patients
doi:10.1371/journal.pone.0049969.t003
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(PDF)
Table S6 List of 124 synergistic natural product combinations
with available cell-based potency data.
(XLSX)
Table S7 Targets and potency-enhancing synergistic molecular
modes in 3 fully or partially sub-potent natural product
combinations with group potencies improved to drug levels.
(PDF)
Table S8 Targets and potency-enhancing molecular interaction
modes in 2 fully sub-potent natural product combinations with
potencies of the principal component increased by .100 fold.
(PDF)
Table S9 Targets and potency-enhancing molecular interaction
modes in 9 fully sub-potent natural product combinations with
potencies of the principal component increased by 10–100 fold.
(PDF)
Table S10 Targets and potency-enhancing molecular interac-
tion modes in 5 fully sub-potent natural product combinations
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